191 related articles for article (PubMed ID: 34067347)
1. High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy.
Krafft U; Olah C; Reis H; Kesch C; Darr C; Grünwald V; Tschirdewahn S; Hadaschik B; Horvath O; Kenessey I; Nyirady P; Varadi M; Modos O; Csizmarik A; Szarvas T
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34067347
[TBL] [Abstract][Full Text] [Related]
2. High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma.
Széles Á; Kovács PT; Csizmarik A; Váradi M; Riesz P; Fazekas T; Váncsa S; Hegyi P; Oláh C; Tschirdewahn S; Darr C; Krafft U; Grünwald V; Hadaschik B; Horváth O; Nyirády P; Szarvas T
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289821
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
Széles Á; Fazekas T; Váncsa S; Váradi M; Kovács PT; Krafft U; Grünwald V; Hadaschik B; Csizmarik A; Hegyi P; Váradi A; Nyirády P; Szarvas T
Cancer Immunol Immunother; 2023 May; 72(5):1061-1073. PubMed ID: 36385210
[TBL] [Abstract][Full Text] [Related]
4. Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
Castello A; Rossi S; Toschi L; Mansi L; Lopci E
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471030
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract][Full Text] [Related]
6. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
7. Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.
Vajavaara H; Mortensen JB; Leivonen SK; Hansen IM; Ludvigsen M; Holte H; Jørgensen J; Bjerre M; d'Amore F; Leppä S
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499013
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of soluble PD-L1 and exosomal PD-L1 in advanced gastric cancer patients receiving systemic chemotherapy.
Shin K; Kim J; Park SJ; Lee MA; Park JM; Choi MG; Kang D; Song KY; Lee HH; Seo HS; Lee SH; Kim B; Kim O; Park J; Kang N; Kim IH
Sci Rep; 2023 Apr; 13(1):6952. PubMed ID: 37117200
[TBL] [Abstract][Full Text] [Related]
9. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients.
Vikerfors A; Davidsson S; Frey J; Jerlström T; Carlsson J
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830993
[TBL] [Abstract][Full Text] [Related]
11. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy.
Fu R; Jing CQ; Li XR; Tan ZF; Li HJ
Cancer Manag Res; 2021; 13():4935-4946. PubMed ID: 34188546
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients.
Kashiwada T; Takano R; Ando F; Kuroda S; Miyabe Y; Owada R; Miyanaga A; Asatsuma-Okumura T; Hashiguchi M; Kanazawa Y; Yoshida H; Seike M; Gemma A; Iwai Y
Front Pharmacol; 2024; 15():1384733. PubMed ID: 38799168
[No Abstract] [Full Text] [Related]
15. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer.
Buderath P; Schwich E; Jensen C; Horn PA; Kimmig R; Kasimir-Bauer S; Rebmann V
Front Oncol; 2019; 9():1015. PubMed ID: 31681568
[No Abstract] [Full Text] [Related]
16. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
Ando K; Hamada K; Watanabe M; Ohkuma R; Shida M; Onoue R; Kubota Y; Matsui H; Ishiguro T; Hirasawa Y; Ariizumi H; Tsurutani J; Yoshimura K; Tsunoda T; Kobayashi S; Wada S
Anticancer Res; 2019 Sep; 39(9):5195-5201. PubMed ID: 31519633
[TBL] [Abstract][Full Text] [Related]
17. High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma.
Guo X; Wang J; Jin J; Chen H; Zhen Z; Jiang W; Lin T; Huang H; Xia Z; Sun X
Transl Oncol; 2018 Jun; 11(3):779-785. PubMed ID: 29698935
[TBL] [Abstract][Full Text] [Related]
18. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
19. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M; Jouinot A; Giroux-Leprieur E; Fabre E; Wislez M; Alifano M; Leroy K; Boudou-Rouquette P; Tlemsani C; Khoudour N; Arrondeau J; Thomas-Schoemann A; Blons H; Mansuet-Lupo A; Damotte D; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32085544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
